HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kole, A. C. Articles by Vaalburg, W. Search for Related Content PubMed PubMed Citation Articles by Kole, A. C. Articles by Vaalburg, W.

Standardized Uptake Value and Quantification of Metabolism for Breast Cancer Imaging with FDG and L-[1-¹¹C]Tyrosine PET

PET Center and Department of Surgical Oncology, Groningen University Hospital, Groningen, The Netherlands
Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands

Correspondence: For correspondence or reprints contact: Annemieke C. Kole, MD, PET Center, Groningen University Hospital, P.O. Box 30.001, 9700 RB Groningen, The NetherlandS.

ABSTRACT

The aims of the study were to compare the value of L-[1-¹¹C]tyrosine (TYR) and ¹⁸Fluoro-2-deoxy-D-glucose (FDG) as tumor tracers in patients with breast cancer, to investigate the correlation between quantitative values and standardized uptake values (SUVs) and to estimate the value of SUVs for the evaluation of therapy. Methods: Eleven patients with one or more malignant breast lesions and two patients with one or more benign breast tumors were studied with TYR and FDG. Doses of 300 MBq of TYR and 230 MBq of FDG were given intravenously. All PET sessions were performed using a Siemens ECAT 951/31 camera. Of 10 malignant tumors and the 3 benign lesions, glucose consumption and protein synthesis rate were quantified. All lesions were studied using SUVs based on body weight, body surface area and lean body mass, with and without correction for plasma glucose or tyrosine levels. Result: All malignant tumors were visualized with both FDG and TYR, but the visual contrast was better with FOG. Increased uptake of the tracers was seen in patients with fibrocystic tissue and complicated the visual assessment and the outlining of tumor tissue. Uptake infibrocystic disease was more prominent with FDG than with TYR. No difference in tumor/nontumor ratio between the two tracers could be established. FDG showed a false-positive result in one benign lesion. No major differences between the SUVs as defined above were found, although the best correlation between glucose consumption and the Suv was observed when the SUV was based on body surface area and corrected for plasma glucose level(r = 0.85–0.87). The SUV based on lean body mass was found to corralate best with protein synthesis rate (r = 0.83–0.94). Conclusion: In this group of patients, TYR appears to be a better tracer than FDG for breast cancer imaging, because of lower uptake in fibrocystic disease. SUVs correlate well with quantitative values, but future studies must determine whether treatment evaluation is also reliable with SUVs.

Key Words: PET • standardized uptake value • fluorine-18-FDG • carbon-11-tyrosine • breast cancer

This article has been cited by other articles:

				C. Plathow and W. A. Weber Tumor Cell Metabolism Imaging J. Nucl. Med., June 1, 2008; 49(Suppl_2): 43S - 63S. [Abstract] [Full Text] [PDF]

				R. Boellaard, N. C. Krak, O. S. Hoekstra, and A. A. Lammertsma Effects of Noise, Image Resolution, and ROI Definition on the Accuracy of Standard Uptake Values: A Simulation Study J. Nucl. Med., September 1, 2004; 45(9): 1519 - 1527. [Abstract] [Full Text] [PDF]

				R. Hustinx, C. Lemaire, G. Jerusalem, P. Moreau, D. Cataldo, B. Duysinx, J. Aerts, M.-F. Fassotte, J. Foidart, and A. Luxen Whole-Body Tumor Imaging Using PET and 2-18F-Fluoro-L-Tyrosine: Preliminary Evaluation and Comparison with 18F-FDG J. Nucl. Med., April 1, 2003; 44(4): 533 - 539. [Abstract] [Full Text] [PDF]

				J. R. de Boer, J. Pruim, B. F.A.M. van der Laan, T. H. Que, A. T.M. Willemsen, F. W.J. Albers, and W. Vaalburg L-1-11C-Tyrosine PET in Patients with Laryngeal Carcinomas: Comparison of Standardized Uptake Value and Protein Synthesis Rate J. Nucl. Med., March 1, 2003; 44(3): 341 - 346. [Abstract] [Full Text] [PDF]

				W. A. Weber, S. Dick, G. Reidl, B. Dzewas, R. Busch, H.-J. Feldmann, M. Molls, C. B. Lumenta, M. Schwaiger, and A. L. Grosu Correlation Between Postoperative 3-[123I]Iodo-L-{alpha}-Methyltyrosine Uptake and Survival in Patients with Gliomas J. Nucl. Med., August 1, 2001; 42(8): 1144 - 1150. [Abstract] [Full Text] [PDF]

				P. L. Jager, W. Vaalburg, J. Pruim, E. G.E. de Vries, K.-J. Langen, and D. A. Piers Radiolabeled Amino Acids: Basic Aspects and Clinical Applications in Oncology J. Nucl. Med., March 1, 2001; 42(3): 432 - 445. [Abstract] [Full Text]

				P. L. Jager, B. E. C. Plaat, E. G. E. de Vries, W. M. Molenaar, W. Vaalburg, D. A. Piers, and H. J. Hoekstra Imaging of Soft-Tissue Tumors Using L-3-[Iodine-123]Iodo-{{alpha}}-methyl-tyrosine Single Photon Emission Computed Tomography: Comparison with Proliferative and Mitotic Activity, Cellularity, and Vascularity Clin. Cancer Res., June 1, 2000; 6(6): 2252 - 2259. [Abstract] [Full Text]